Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BridgeBio
Pharma
Trial results set up BioMarin for expansion of Voxzogo
With phase 3 results that have “exceeded” its expectations, BioMarin looks set up to gain a label expansion for dwarfism drug Voxzogo.
Kevin Dunleavy
May 21, 2026 10:23am
Pfizer fends off generic Vyndamax entry until 2031
Apr 28, 2026 4:30pm
Pfizer inks settlements with 2 generic Vyndamax contenders
Apr 27, 2026 11:23am
As questions swirl, Alnylam eyes ATTR market leadership by 2030
Mar 26, 2026 2:08pm
FDA approves Ascendis' achondroplasia treatment Yuviwel
Mar 2, 2026 9:25am
BridgeBio CEO shrugs off recent Attruby pricing pressure fears
Feb 25, 2026 2:30pm
